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Abstract 
Healthcare costs are constantly rising all over the world and healthcare technologies that 
can reduce costs and enhance health outcomes can potentially provide a solution to this 
global problem. Health outcomes research is performed nationally and internationally to 
evaluate the outcomes of new health interventions, technologies, and pharmaceuticals 
along with their cost and burden for society. Comparing the positive or negative effects 
of health technologies and medications is important for healthcare policy making and 
reimbursement strategies. One of the important methods to evaluate health outcomes is 
measurement of health related quality of life.  
Health Related Quality of Life (HRQoL) is a concept that has important uses in research 
and comprehensive care of patients with chronic illnesses. HRQoL can be measured by 
using a classification system consisting of a set of attributes with multiple levels per 
attribute. One approach to evaluate HRQoL uses questionnaires which derive preference-
based measures of health utility, based on a measurement system that allows patients to 
describe impacts on their health and assigns a utility score between 0 (death) and 1 
(perfect health) to those descriptions. These questionnaires are called Multi Attribute 
Utility Instruments (MAUIs) and are the most widely used method to measure health 
utilities. 
HRQoL can be measured with generic or disease-specific instruments. Generic 
instruments are those that are broadly applicable across types and severities of disease, 
across different health interventions, and across demographic and cultural subgroups. 
They are designed to summarize all concepts of HRQoL that apply to many different 
impairments, illnesses, patients and populations. Disease-specific measures are those that 
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are designed to assess specific diagnostic groups or patient populations. These measures 
are particularly useful when there they are focused on clinically important changes.  
It has been argued that generic instruments are insensitive to the health burdens imposed 
by hemophilia, and to precisely measure HRQoL of patients with a specific disease, we 
should use a targeted or a disease-specific instrument.  
Disease-specific HRQoL utility assessments can be used for conducting Cost Utility 
Analysis (CUA) to allocate resources amongst patients with the same disease. On the 
other hand, in order to run CUA studies for resource allocation purposes across different 
diseases, we are dependent on generic utility measures.  
The purpose of this study was to determine if a generic HRQoL assessment provides 
relevant utility values in hemophilia patients.  We measured HRQoL of hemophilia 
patients using the EQ-5D-5L (a generic MAUI) and Haemo-QoL-A (a disease –specific 
descriptive health profile). Significant correlations were found between the utility scores 
measured by the generic tool EQ-5D-5L and the HRQoL scores measured by Haemo 
QoL A. Overall, the association between Haemo-QoL-A and EQ-5D-5L was stronger 
between the total scores as opposed to the domain scores. Associations with Haemo-
QoL-A were strongest with the EQ-5D-5L utility scores that were generated using the 
direct conversion method as opposed to cross-walk valuations based on the extension of 
the older 3-level EQ-5D-3L utility scores.  
It can be concluded that the utility scores associated with EQ-5D-5L are sufficiently 
correlated (correlation coefficient equal or greater than 0.7) with the HRQoL scores and 
thus, EQ-5D-5L can be used in hemophilia patient population for calculating the utilities 
required for resource allocation purposes. 
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Chapter 1 – Introduction and Literature Review  
 
Health Related Quality of Life (HRQoL) is a concept that has important uses in 
research and comprehensive care of the patients with chronic illnesses (Drotar, 1998). 
The inclusion of HRQoL in medical research plays an important role to address the 
patients’ perspectives of their health conditions and the available treatments (Bullinger et 
al, 2009). HRQoL can be measured by standardized and validated Multi Attribute Utility 
Instruments (MAUI) that describe health states using a classification system consisting of 
a set of attributes with multiple levels per attribute (Torrence, 1996). According to 
McCaffrey et al (2016), generic MAUIs have two main elements: a set of items with 
multiple response categories covering different dimensions of HRQoL (descriptive 
system), and a MAUI developer-created scoring algorithm indicating the strength of 
preference for the health states defined by the instrument (quality weights). Development 
of the scoring algorithm associated with a MAUI is usually done by one of the two main 
methods: Time Trade Off (TTO) and Standard Gamble. Although there are different 
methods to design TTO studies all MAUI development studies that use TTO method to 
value health utility share the core element of trading length of life for quality of life 
(Attema et al, 2013). Standard gamble method is also based on the subjects’ preference 
for measurement of individuals' preferences under uncertainty and to express the outcome 
of different therapeutic choices in utility values (Gafni, 1994). 
As a generic HRQoL measure, a MAUI is directly applicable to policy and 
resource allocation because the scoring algorithm converts the vector of attribute scores 
into a single number called a utility, usually scored from 0= death to 1=optimal HRQoL.  
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With MAUIs, utilities can be measured over a patient population and multiplied by 
patient survival to create Quality-Adjusted Life Years (QALYs). Health utility is typically 
measured using generic quality of life measurement tools such as the EuroQol-5D-5L 
(EQ-5D-5L).  
 
Generics vs. Disease Specific HRQoL Measurement 
The comparison between the generic and the disease-specific HRQoL measures 
has been discussed in the literature for several decades. The generic measures are 
designed to be applicable to persons with a variety of health conditions including the 
general population which consists mainly of people with no disease or defined health 
conditions. Disease-specific measures on the other hand are designed for a defined 
clinical population with a focus on the most relevant health issues of that group 
(Bullinger et al, 2009). In a study of the generic and disease-specific tools, Patrick and 
Deyo (1989) emphasized research opportunities for both generic and disease-specific 
research. They also reviewed the technical requirements associated with each application 
along with the advantages and disadvantages of generic and disease-specific 
measurement tools. According to Patrick and Deyo (1989), although the advantages and 
disadvantages of generic and disease-specific measures primarily depend on the specific 
objective and application of the measurement in clinical research, practice, or policy 
analysis, and the technical requirements of validity, reliability, and generalizability apply 
to all of the tools.  
Since the content validity depends on the extent to which and empirical 
measurement reflects the full domain relevant to a particular situation, disease-specific 
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measures are expected to have better content validity compared to generic measures. 
Construct validity on the other hand refers to the extent to which results from a given 
instrument relate to other measures in a manner consistent with theoretical hypotheses. In 
other words, it means that an instrument measures what it purports to measure, and 
therefore relationships between that instrument and measures of other concepts and 
variables are consistent with expectations based on theory. Studying the correlation 
between the generic and disease-specific measures and their application for different 
disease types/severities helps in studying the construct validity of the measurement tools. 
Internal consistency is usually measured in both generic and disease-specific tools to 
study the reliability of them. The reliability of the disease-specific measures is expected 
to be lower than the generic ones because the specific questions about the diseases 
features are expected to vary more compared to the general questions asked in generic 
tools. In order to study the generalizability of the tools it is required to look at the 
comparability across the different diseases, conditions, and populations. This is an 
important advantage of the generic measurement tool that may be administered to 
different populations with different diseases. Wells et al (2011) also studied generic and 
disease-specific measurement tools and summarized the advantages associated with each 
tool. Aligned with the previous work of Patrick and Deyo, Wells notes that while generic 
measures have broad application across different types and severity of diseases, disease-
specific measures are specifically designed to assess particular diseases or patient 
populations. Coons et al (2000) compared 7 different generic HRQoL measurement tools 
and studied validity, reliability and cultural and language adaptation associated with each 
measurement tool. They concluded that the choice will depend on a variety of factors 
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including the characteristics of the population (e.g. age, health status, and 
language/culture) and the environment in which the measurement is undertaken (e.g. 
clinical trial, routine physician visit).  
Generic HRQoL measures have been subject to criticism too. Papaionnou et al 
(2011) studied three generic HRQoL measurement tools in schizophrenia patient 
population and raised doubts about the use of generic measures of health in patients with 
schizophrenia. They reviewed thirty three studies that provided data on the validity of the 
generic instruments and they found the evidence for convergent validity and 
responsiveness mixed, with studies presenting contradictory results. 
Choosing the appropriate HRQoL measurement tools is important in conducting 
research. Although validity, reliability, and generalizability are essential requirements for 
all HRQoL tools, there are other features that impact the selection of an appropriate tool 
for a particular application. Chen et al. (2005) state that the HRQoL tools in routine 
general practice need to be simple, fast to complete, easy to score, and provide data 
useful to clinicians. Also, they suggest a few other qualifications in the process of 
choosing HRQoL measurement tools. They recommend using tools with relevant 
domains that have been tested before in the relevant population, tools whose floor and 
ceiling effects have been evaluated. They also looked at the advantages and 
disadvantages of generic versus disease-specific tools. According to their study, the 
advantages of generic instruments include being applicable to all persons irrespective of 
their type or number of illness. In contrast, the disease-specific measures are more 
specific and sensitive. In terms of disadvantages, the generic tools may not be sensitive to 
some problems unique to a specific disease while disease-specific tools make comparison 
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between different patient groups difficult. Furthermore, the results of disease specific 
instruments are difficult to interpret in persons with multiple diseases. 
 
 
Table 1: Summary of the advantages and disadvantages of generic and disease-specific 
HRQoL measurement tools 
 
  
Advantages Disadvantages 
Generic HRQoL Measures 
Broad application 
across different types 
and severity of 
diseases 
Not sensitive to some 
problems unique to a specific 
disease 
Being applicable to 
all persons 
irrespective of their 
type or number of 
illnesses 
 
 
Contradictory  results in 
convergent validity and 
responsiveness of generic 
HRQoL tools in certain 
diseases e.g Schizophrenia 
Disease-Specific HRQoL Measures 
More specific and 
sensitive 
Make comparison between 
different patient groups 
difficult 
Designed to assess 
particular diseases or 
patient populations 
Difficult to interpret in persons 
with multiple diseases 
 
 
Hemophilia-Specific HRQoL Measurement 
Choosing an appropriate generic HRQoL tool for the hemophilia patient 
population is not an exception from the selection criteria discussed above. It has been 
argued that generic tools are insensitive to the health burdens imposed by hemophilia. 
The need for disease-specific QoL measures for hemophilia has been addressed in the 
literature (Whitehead and Ali (2010). According to Gringeri and Von Mackensen (2008), 
if we want to precisely measure HRQoL of patients with a specific disease, we should use 
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a targeted or a disease-specific questionnaire. Moreover, disease-specific HRQoL can be 
used for conducting Cost Utility Analysis (CUA) to allocate resources amongst patients 
with the same disease. On the other hand, in order to run CUA studies for resource 
allocation purposes across different diseases, we are dependent on generic utility 
measures such as EQ-5D-5L. The relationship between hemophilia-specific HRQoL 
measures and generic utility measures has not been established. We hypothesized that the 
generic HRQoL measure, EQ-5D-5L, and a rigorously validated disease-specific 
measure, the Haemo-QoL-A, would be strongly correlated (r> 0.70, corresponding to 
approximately 50% shared variance). If the hypothesis is confirmed, this will establish 
that the EQ-5D-5L can be confidently used in CUA studies associated with adult 
hemophilia population.  Because there are currently several EQ-5D-5L utility value sets, 
for this study we used the following set as our standard (euroqol.org, 2017), and as an 
exploratory aim, compared agreement between the leading crosswalk and direct 
evaluation value sets (Feng et al, 2016). The purpose of this study is to determine if a 
generic HRQoL assessment provides relevant utility values in hemophilia patients.  We 
measured HRQoL of hemophilia patients using EQ-5D-5L (a generic tool) and Haemo-
QoL-A (a disease –specific tool). Patient participation in the study was voluntary and the 
recruitment done through a patient support group. Rare Patient Voice, a patient support 
group, sent the link to participate in the study, or the hard copy of the questionnaires to 
the hemophilia patients registered at this group. According to Rare Patient Voice 
management, there are 292 hemophilia patients registered in this group and they are 
broadly distributed across the US. The study received completed study questionnaires 
 7 
 
from 153 hemophilia patients. The responses were analyzed using Excel and SPSS 
software and the results are discussed in detail.  
 
Background and Significance of the Study 
Hemophilia is a rare, X-linked, recessive congenital bleeding disorder caused by a 
deficiency or complete absence of coagulation factor VIII (FVIII) in hemophilia A, or 
factor IX (FIX) in hemophilia B. The incidence of Hemophilia is 1:10,000 of total births 
or 1:5,000 of male births (Knight, 2005), and represents around 400 hemophilia births in 
the United States each year. Based upon the coagulation level in plasma, hemophilia is 
classified as severe (factor level <1 IU/dl, <1% of normal) – representing approximately 
60% of cases, moderate (factor level = 1-5 IU/dl, 1-5% of normal) – representing 
approximately 15% of cases, and mild (factor level = 6-49 IU/dl, 6-49% of normal) – 
representing approximately 25% of cases (National Hemophilia Foundation, 2016). 
Severe and moderate patients need to be treated. They may bleed spontaneously 
or after minor injuries. These bleedings result in advanced degenerative joint damage 
over time and may require joint replacements (Knight, 2005). Treatment of hemophilia is 
based on replacement of the missing clotting factor and the administration of the factor 
can be through on-demand or prophylaxis treatment. However, the dose, frequency, and 
type of replacement vary depending not only to the severity of the disease and the patient 
status, but also on availability of the factor concentrates, reimbursement and the 
distribution system in the country/state in which the treatment is being given (Bullinger et 
al, 2009). 
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Hemophilia impacts the quality of life of patients through disability, pain, 
caregiving issues, and exposure to HIV virus and other blood-borne diseases (Escobar, 
2010). About 50-80% of the treatment cost in hemophilia is related to the costs associated 
with coagulation factors (Knight, 2005). Since coagulation factors are expensive products 
and may be covered by health reimbursement systems, CUA studies are important to 
justify expenditures.  Cost-utility analysis is useful to determine the priorities of resource 
allocation for hemophilia treatment (Colombo et al, 2011). Baseline HRQoL in 
hemophilia patients assessed with MAUIs, can be converted into QALYs for use in these 
cost-utility studies. 
 
Specific Aims 
The overall objective of this study was to evaluate the performance of the EQ-5D-
5L in covering the health problems relevant to hemophilia. The specific aims of the study 
were to: 
 
1. Evaluate the reliability of Haemo-QoL-A in hemophilia patients. 
Cronbach’s α, which measures the internal consistency of items 
hypothesized to measure a single construct using the average inter-item 
correlations (Fayers and Machin, 2007), will be used to measure the 
reliability of the Haemo-QoL-A, overall and within domains. 
2. To assess the construct validity of EQ-5D-5L in measuring HRQoL in US 
patients with hemophilia. 
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a. Construct validity is defined as the degree to which an instrument 
measures the construct that it is designed to measure (Fayers and 
Machin, 2007). For this study, responses on the Haemo-QOL-A were 
considered patients’ “true” HRQoL, and the EQ-5D-5L results will be 
compared to this criterion in two ways: by assessing concurrent 
validity (measured by correlations between comparable domains 
assess by the questionnaires), and known group differences.  Known 
group comparisons are tests of validity and a form of sensitivity or 
responsiveness assessment (Fayers and Machin, 2007).  
b. Evaluate correlations between the total HRQoL score obtained from 
the total Haemo-QoL-A and the scores associated with total score and 
each domain of EQ-5D-5L. 
c. Examine floor and ceiling effects in EQ-5D-5L to ensure that the 
instrument covers the full range of severity and allowed for 
discrimination among the subjects. 
d. Evaluating the Content Validity of EQ-5D-5L relative to Haemo-QoL-
A. Responses to the Haemo QoL questions that are expected to have 
similar responses in EQ-5D-5L will be tabulated and compared using 
correlation coefficients. Content validity will be supported if the 
Haemo-QoL-A answers correlate with the EQ-5D-5L questions that 
measure the similar concept with at least 25% shared variance. 
3. Compare the two approaches of valuing the EQ-5D-5L (crosswalk 
approach and direct measurement approach) on aims 1-2.  
 10 
 
Utility values described by HRQoL instruments are either directly 
measured using a valuation technique such as time trade off or standard 
gamble, or estimated using a mapping function from known utility values 
defined by another HRQoL instrument (Luo, 2015). EQ-5D-5L crosswalk 
value set is mapped from the known EQ-5D-3L values.  
The first complete value set of EQ-5D-5L was created with the direct 
technique of time trade off by Feng et al (2016) in Canada. Agreement 
between the two valuation methods will be assessed. The aim is to 
determine if the utility score obtained from one approach correlates with 
more strongly with Haemo-QoL-A domain scores and have larger between 
group effect sizes compared to the other approach and if the floor and 
ceiling effects are smaller with one approach or the other. We evaluated 
the difference between the total health scores obtained from crosswalk 
approach and direct reference approach using ANOVA. 
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Chapter 2 – Research Design and Methodology   
The high cost of hemophilia treatment is an economic burden and cost-utility 
studies help to identify cost effective treatments that provide better health outcomes. 
HRQoL tools that measure health utilities are essential for cost utility studies. The generic 
HRQoL measure, EQ-5D is widely used for CUA, and has been previously used in 
several cost utility studies in hemophilia. The instrument was initially designed in 1990 
with 5 domains of mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression and each domain had only 3 response levels of no problems, some 
problems, and extreme problems. The newer version of the instrument, EQ-5D-5L, was 
released in 2009 with the same domains and with 5 response levels (euroqol.com, 2017). 
The validity of EQ-5D-5L for hemophilia studies needs to be established and therefore, 
the EQ-5D-5L is chosen for this study.  
The need for development of a valid disease-specific HRQoL measure in 
hemophilia has been emphasized by Fischer et al (2003) and later by Remor et al (2004). 
Rentz et al (2008) worked on development and validation of Heamo-QoL-A as disease-
specific HRQoL measures designed to address problems relevant to hemophilia and 
reflect the multi-dimensional nature of the disease. The Haemo-QoL-A is used for this 
study because it has been shown to have discriminatory power for disease severity and its 
validity has been evaluated in independent research studies (Rentz, 2008). 
 
Sample and Inclusion Criteria:  
The target population for this study is adult Hemophilia A patients registered in 
Rare Patient Voice patient support group. Hemophilia patients are almost entirely male 
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individuals. Hemophilia A is characterized by deficiency in factor VIII clotting activity 
that results in prolonged oozing after injuries, tooth extractions, or surgery, and delayed 
or recurrent bleeding prior to complete wound healing (Konkle et al, 2011).  Inclusion 
criteria are: Diagnosis of Hemophilia A (mild, moderate, and severe cases are included), 
ability to read and write English, 18 years of age or older.  
 
Sample Size 
The sample size was based on Rare Patient Voice data. According to Rare Patient 
Voice (2017) the total number of the Hemophilia patients registered in this patient 
support group was 292 patients who are broadly distributed across USA and based on 
their experience, 100 patients were expected to participate in the study. The number 
includes mild, moderate, and severe hemophilia cases. Severe hemophilia patients 
represent 60% of total hemophilia cases (National Hemophilia Foundation, 2016). We 
assumed that the severity distribution amongst patients in the Rare Patient Voice database 
was similar to national rates. We expected that about 30-35% of hemophilia patients 
(mild, moderate and severe cases) will participate in this study.  
 
Patient Recruitment 
The patients were recruited by Rare Patient Voice. The patients were completely 
anonymous to the researchers. The link for the study questionnaires were sent to the 
registered hemophilia patients by Rare Patient Voice via the Qualtrics platform. Rare 
Patient Voice is a patient support group that is specialized in healthcare market research 
and provides patients and caregivers with rare diseases an opportunity to voice their 
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opinions through surveys and interviews to improve medical products and services. 
(rarepatientvoice.com, 2017).153 patients completed the questionnaires. The researchers 
could only access the questionnaire results stored in Qualtrics.   
The patients were informed about the study in an email from the Rare Patient 
Voice team (Appendix 1), and interested patients were instructed to access the link to the 
Qualtrics website to complete the study questionnaires. 
Missing items for the Heamo-QoL- A were handled in accordance with the 
Scoring Manual for Haemo-QoL-A (Appendix 2). For the subscale analyses, if < 50% of 
the scale items were missing, the mean scale score of the items present were used to 
impute a score for the missing items.  If > 50% of the items were missing, no scale score 
was calculated, the subscale score was considered missing.  If a subscale score is missing, 
the Haemo-QoL-A total score cannot be calculated.  There was no missing data for the 
EQ-5D-5L. 
 
HRQoL Measures 
Generic Measure 
We used EQ-5D-5L as a generic MAUI and a patient-reported outcomes (PRO) 
instrument to determine the quality of life in hemophilia patients. Using PRO as the 
instrument to measure HRQoL provided us with some advantages. The first advantage 
was that we received the reports directly from the patients and captured their perspective 
about how they function or feel in relation to their current health status. Second, the 
results were without any interpretation by physicians or pharmaceutical manufacturers or 
third party payers. The patient reported outcomes and the importance of including the 
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patients’ opinions in decision making process has been discussed in the recent literature. 
It is emphasized in some available literature that encouraging patients to take 
responsibility for their health was the best way to ensure health system sustainability 
(Smith et al, 2009). Xu et al (2017) used EQ-5D-5L to study the relationship between 
shared decision-making and health-related quality of life. They found direct relationship 
between HRQoL and shared decision-making. According to their study, the patients 
partially involved in decision-making had higher HRQoL scores than the other 
involvement groups, even when adjusting for demographic, socioeconomic and health-
related factors.  
EQ-5D-5L is a standardized measure of health status that provides a simple, 
generic measure of health for clinical and economic appraisal (Health Policy, 1990). EQ-
5D-5L is applicable to a wide range of health conditions and treatments and is known as a 
tool suited for use in clinics and in face-to-face interviews. It provides a simple 
descriptive profile and a single index value for health status that can be used in clinical 
and economic evaluation of health care. The EQ-5D-5L descriptive system comprises the 
5 domains of mobility, self-care, usual activities, pain/discomfort, and anxiety depression. 
Responses are recorded at 5 levels (no problems, slight problems, moderate problems, 
severe problems, unable/extreme problems) for each dimension. The instrument has been 
developed from the older version EQ-5D-3L that also has the same domains but it 
describes the problems in each domain into 3 levels (no problems, some/moderate 
problems, and unable/extreme problems) rather than 5 levels in newer EQ-5D-5L.  
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According to euroqol.com (2017) the EQ-5D-5L was introduced to improve 
sensitivity and to reduce the ceiling effects compared to the older version EQ-5D-3L 
which had only three response levels. 
There is also a Visual Analogue Scale (EQ VAS) designed in the tool that records 
the respondents’ self-rated health on a vertical, visual analogue scale ranging from the 
“Best Imaginable” or score 100 to the “Worst Imaginable” health state or score 0. 
(Euroqol.com, 2015).   
 The EQ-5D-5L is short and written in straight forward language (Table 2).   
Table 2: Example of an EQ-5D-5L questionnaire completed by two patients (Patient 
ID#1001 and Patient ID#1002) 
 
Variable 
Name Self-Care Activity Mobility Pain Anxiety Sate 
EQ-
VAS 
  
1 = No 
Problems 
1 = No 
Problems 
1 = No 
Problems 
1 = No 
Pain 
1 = Not 
Anxious     
  
 
2 = Slight 
Problems 
2 = Slight 
Problems 
2 = Slight 
Problems 
2 = Slight 
Pain 
2 = Slightly 
Anxious 
5 Digit 
Code     
  
3 = Moderate 
Problems 
3 = Moderate 
Problems 
3 = Moderate 
Problems 
 
3 = 
Moderate 
Pain 
3 = 
Moderately 
Anxious  from  
999 - 
Missing  
Variable 
Description 
4 = Severe 
Problems 
4 = Severe 
Problems 
4 = Severe 
Problems 
 
4 = Severe 
Pain 
4 = Severely 
Anxious 
EQ-
5D-5L Value 
  5 = Unable to 5 = Unable to 5 = Unable to 
 
5 = 
Extreme 
Pain 
5 = 
Extremely 
Anxious     
  
9 = Missing 
Value 
9 = Missing 
Value 
9 = Missing 
Value 
 
9 = 
Missing 
Value 
9 = Missing 
Value     
                
Patient ID# 
1001 1 1 1 1 1 11111 100 
Patient ID# 
1002 3 3 3 3 3 33333 50 
 
A health utility value index is used to convert each patient’s five digit EQ-5D-5L 
code to a single health state between 0 and 1 at which 1 is perfect health and 0 is death. 
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Every set of the 5 digits represents a unique health state.  The actual utility value of each 
5 digit score (for example for 11111 and 33333) is based on the valuation index set. 
 
There are two main valuation techniques to convert the health scores to the health 
states. According to Luo et al (2015) the health state values can either be measured using 
a direct valuation technique such as Time Trade Off (TTO), or they can be estimated 
using a mapping function from a known set of utility values defined by another HRQoL 
measure. The available EQ-5D-5L “crosswalk” value set for United States in Euro-QoL 
website (2017) was created from the currently available EQ-5D-3L value set using the 
mapping technique.(Euroqol.org, 2017)  According to euroqol.com (2017) “crosswalk 
was based on a response mapping approach that estimated the relationship between 
responses to the EQ-5D-3L (‘3L’) and EQ-5D-5L (‘5L’) descriptive systems, and 
subsequently established a link to the 3L value sets.” Xie et al (2016) set up a country 
specific EQ-5D-5L value set for Canada using the direct method of TTO with a sample of 
1209 patients and classified these patients into 86 health states. 
 
Disease-Specific Measure 
Haemo-QoL-A is a hemophilia-specific HRQoL descriptive health profile 
designed for adult hemophilia patients. It was designed for adults 18 years of age and 
older and includes 41 items in 6 domains of physical functioning, role functioning, worry, 
consequences of bleeding, emotional impact, and treatment concerns. Rentz et al (2008) 
evaluated the content validity of the Haemo-QoL-A by examining its correlations with a 
generic HRQoL measure, Health Assessment Questionnaire – Functional Disability Index 
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(HAQ-FDI) and the Overall Treatment Effect (OTE) scale in a sample of 221 patients. 
Using Cronbach’s α at baseline and week 4 of their study they found the Haemo-QoL-A 
to be a reliable measures of HRQoL for hemophilia patients. Rentz ‘s study reported a 
Cronbach’s α of 0.95 for the total overall score of the Haemo-QoL-A, which indicates 
high reliability, since a Cronbach’s α of ≥0.70 is generally considered sufficient 
instrument reliability for comparing groups. 
 Responses to Haemo-QoL-A questions are recorded in 6 levels on a frequency 
scale: none of the time, a little of the time, some of the time, a good bit of the time, most 
of the time, and all of the time.  Responses are then coded to provide overall and domain-
specific health scores. Domain scores are calculated by taking the mean of the items in 
each domain and transforming them to 0 (none or absent) to 100 (very severe) scale. The 
scoring manual of Haemo-QoL-A is provided in Appendix 2. 
Young et al (2012) also validated Haemo-QoL-A in a Canadian French speaking 
population by examining its correlation with the generic SF36 in a sample of 22 adult 
men with hemophilia, 19 boys with hemophilia and 19 parents. The Haemo-QoL-A had 
good test retest reproducibility that exceeded 0.78 in all domains and a generally good 
concurrent validity with total and subscale scores across the different domains with SF-36 
(Rentz et al, 2008). This tool also can discriminate adult hemophilia patients by severity 
of disease and by treatment protocols (On demand vs. prophylaxis). Because the Haemo-
QoL-A has discriminatory power for disease severity and its validity has been evaluated 
in independent research studies, it was selected for this dissertation. 
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Informed Consent 
The study subjects are adult patients over 18 years of age. The IRB approved this 
dissertation project as an exempt study since the questionnaire did not include sensitive 
questions that these individuals wouldn’t encounter in their everyday life, and the 
patients’ identities would not be revealed to the researcher. Choosing to access the 
Qualtrics link to the study questionnaires was voluntary, and there was no separate 
consent form. 
 
Study Setting and Procedures:  
The study was implemented in 3 steps: 
Step 1: Patient Recruitment. The patients in the Rare Voice hemophilia support 
group were notified about the study and given access to the study questionnaires via a 
link to the study’s Qualtrics website.  
Step 2: Interested patients completed the study questionnaire via the link to the 
Qualtrics online platform.  
Step 3: Data were exported from Qualtrics to the investigator for analysis. 
 
Data Collection 
The study questionnaire consisted of the EQ-5D-5L, the EQ-5D VAS, the Haemo-
QoL-A HRQoL descriptive health profile, a qualitative item - “name the most important 
determinant of your quality of life”, and two additional health questions: factor level and 
disease severity.  The questionnaires were self-administered. No data was required in 
respect with the treatment protocol used by participants. 
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Qualtrics online platform provided easy and reliable access for the participants 
(qualtrics.com, 2017).  
 
Data Analysis    
1. Validity: We used statistical analysis to study the validity of EQ-5D-5L in 
measuring HRQoL in hemophilia patient population. 
a) Construct validity was studied to find if the different measures of HRQoL 
for Hemophilia patients in the two measurement tools are in fact related. 
Construct Validity is defined as the degree to which an instrument 
measures the construct that it is designed to measure (Fayers and Machin, 
2007). Construct validity is determined in a number ways such as 
concurrent validity and known-groups validation. In this study the 
concurrent criterion validity and known group differences will be 
examined using Pearson’s Correlation Coefficient, floor and ceiling 
effects, and ANOVA methods.  
b) The concurrent validity will be supported if EQ-5D-5L score is strongly 
correlated (> 0.70) with the domains of Haemo-QoL-A, physical 
functioning, role functioning, worry, consequences of bleeding, emotional 
impact, and treatment concerns. Rentz et al (2008) arbitrarily chose 
correlation coefficient threshold of > 0.4 for demonstrating construct 
validity. Criterion validity determines the agreement to a true value 
(Fayers and Machin, 2007). In this study, Haemo-QoL-A is considered the 
criterion or true HRQoL state. The correlation among EQ-5D-5L average 
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scores and utility scores with overall HRQoL score and the scores of each 
Haemo-QoL-A domain were studied. The construct validity of EQ-5D-5L 
for use in the hemophilia patient population will be supported if the 
correlation coefficient value between utility scores and total Haemo-QoL-
A scores is greater than 0.4. The two measurement tools will be considered 
strongly correlated if the correlation coefficient value is equal or greater 
than 0.7. According to Mukaka (2012) a correlation coefficient value 
between 0.5 and 0.7 is considered evidence that two instruments used in 
medical research are moderately correlated, and a value between 0.3 and 
0.5 is considered evidence that the instruments are weakly correlated. Any 
value lower than 0.3 is considered negligible. 
We hypothesized that the correlation between the utility score calculated 
with both direct and crosswalk methods for the EQ-5D-5L and the total 
score of the Haemo-QoL-A will be moderate to strong. We also 
hypothesized that the similar domains in each instrument will be 
moderately to strongly correlated. 
c) Floor and ceiling effect: In order to study the full range of scores 
associated with Haemo-QoL-A and EQ-5D-5L items, and make sure that 
the items discriminated well at very low and at very high levels of the 
traits being measured we looked at the proportion of the responders who 
chose the highest possible score (ceiling effect) and the proportion of the 
responders who chose the lowest possible score (floor effect). According 
to Petrillo et al (2015) at least 5% but not more than 40% selecting the 
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extreme categories is considered acceptable in patient-reported outcomes 
(PRO) studies. We propose to use 20% as the threshold as for floor and 
ceiling effect to study if the instrument is able to discriminate among the 
disease severity levels, cover the full range of severity in patients, and 
allow for discrimination between the subjects (Fayers and Machin, 2007). 
Floor effect will be considered present if 20% of the responders select the 
worst score. Ceiling Effect will be considered present if 20% of the 
responders select the highest score.  
Known-group validation is used based on the assumption that the greater 
the severity of hemophilia, the worse patients’ HRQoL. Therefore, the 
instruments should be sensitive to differences in the HRQoL reported by 
patients with mild, moderate, and severe hemophilia. As another method 
to evaluate the construct validity of EQ-5D-5L to be used for hemophilia 
patients we looked at the ability of EQ-5D-5L domain scores and utility 
scores and Haemo-QoL-A domains scores and total score to discriminate 
hemophilia patients based on the severity of the disease (mild, moderate, 
and severe). We use ANOVA methods to compare the utility scores 
measured by EQ-5D-5L. ANOVA model included severity - mild, 
moderate, and severe hemophilia disease states - as the independent 
variable and HRQoL subscales, total score, and EQ-VAS total score as 
dependent variables. The objective is to find out if the HRQoL utility 
scores can discriminate the patients with Mild, Moderate, and Severe 
hemophilia. We studied the P value of ANOVAs, and the relative validity 
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of the two measures was compared based on the magnitude of the ratio of 
their F-statistics (Rentz et al, 2008). 
d) Content Validity of EQ-5D-5L relative to Haemo-QoL-A was evaluated by 
studying the correlation between the mean scores of each EQ-5D-5L 
domains and the mean scores associated with the questions that should 
have similar answers on the Haemo-QoL-A. All 41 questions of the 
Haemo-QoL-A were reviewed and the questions that were expected to 
have similar answers with any of the five EQ-5D-5L questions were 
identified and the correlation between the mean scores of each set of 
questions with the average score of the corresponding question in EQ-5D-
5L instrument was calculated. See Appendix 3.  
2. Internal Consistency Reliability associated with Haemo-QoL-A scores was 
obtained for each domain: physical functioning, role functioning, worry, 
consequences of bleeding, emotional impact, and treatment concerns.  Internal 
consistency is based on the correlations between the different items in the same 
test. It measures whether several items that propose to measure the same general 
construct produce similar scores. Since we are trying to evaluate and compare the 
different items that measure the domains of HRQoL in Hemophilia patients we 
use Cronbach’s α as our method for measuring internal consistency within each 
domain and overall.  
The resulting α coefficient of reliability ranges from 0 to 1. According to Goforth 
(2015) If all of the scale items are entirely independent from one another (i.e., are 
not correlated or share no covariance), then α = 0; and, if all of the items have 
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high covariance, then α will approach 1 as the number of items in the scale 
approaches infinity. As a result, the higher α coefficient is indicative of a higher 
probably to measure the same underlying concept. Although there is no standard 
threshold for Cronbach’s α to be considered for evaluating internal consistency, it 
is generally accepted that a Cronbach’s α value greater than 0.7 is usually 
acceptable and a Cronbach’s α value lower than 0.5 is considered unacceptable. 
Rentz et al (2008) considered Cronbach’s α greater than 0.7 sufficient for group-
level internal comparisons in their study of Haemo-QoL-A. 
3. The crosswalk value set and direct value set will be used in order to convert the 
value scores of the hemophilia patient sample to utilities. The distributions of the 
value-based and mapped EQ-5D-5L utilities will be compared. Luo et al (2015) 
have shown that direct method utility scores are generally higher than the 
crosswalk scores, and hence may increase the possibility of ceiling effect in this 
method. However, in their study the magnitude of the effect was small and the 
corresponding 90% CI fell within the pre-specified equivalence margin. The mean 
scores associated with each conversion method and the standard deviations of the 
two conversion approaches will be compared for the entire hemophilia sample.  
We will use scatter plot and comparison to the 45 degree line of perfect agreement 
to compare the results associated with each approach. We set the x axis and y axis 
of the scatter plot to the range of 0 to 1 for the 45 degree line to serve as the 
identify line in our analysis. The equivalence of the two approaches will be 
assessed by comparing 90% confidence interval (CIs) of the differences with the 
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predefined equivalence margin of 0.05. This is consistent with the previous 
research (Luo, 2015). 
We use Time Trade off-Derived Canada EQ-5D-5L Value set to convert the 
obtained score to utilities. The validity of this method has been evaluated and 
confirmed by Xie et al (2016). We will also use the US crosswalk Value Set that 
was developed by the EQ5D team to convert the scores to utilities and we will 
compare the results with the Canada Value Set. The strength of the correlation 
between each utility conversion method and Haemo-QoL-A scores determines if 
one method provides better correlation and hence, be preferred to be used in 
hemophilia patient population.  We will use correlation coefficients to find out 
which conversion method yields scores that are more strongly correlated to 
Haemo-QoL-A and EQ5D VAS results. 
 
Excel Data Analysis tool pack (XLSTAT) was used in order to analyze the data and 
provide the statistical information. XLSTAT is a user-friendly statistical software for 
Microsoft Excel. It is the most complete and widely used data analysis add-on for Excel. 
 
Impacts of Findings and Relevance to Social and Administrative Pharmacy: 
Comparison between a disease-specific instrument validated to describe 
hemophilia patient HRQoL and a widely used generic instrument that provides health 
utilities will establish if we can confidently use this generic HRQoL tool for 
administrative and social evaluations for hemophilia patients. An important 
administrative consideration with respect to hemophilia is the economic burden of 
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disease and resource allocation. Cost-utility studies that include QALY evaluations show 
the overall HRQoL and the cost associated with improvement. An important advantage of 
using valid and reliable generic HRQoL tools is the ability to compare the cost and 
burden of hemophilia with the cost and burden of the other diseases and to facilitate 
resource allocation decisions along with the priority setting among the different diseases. 
As a result, these methods are used in determining outcome based resource allocation 
policies. Our study contributes in this social and economic context by evaluating the 
pragmatic validity of a generic measure that can potentially be used in future cost-utility 
studies.    
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Chapter 3 – Study Results 
Study Subjects 
A total of 156 persons (142 men and 14 women) responded to the Rare Patient 
Voice study invitation and completed a survey. Six patients skipped one item and one 
patient skipped two item on the Haemo-QoL-A, and all these questionnaires could be 
fully scored. Three patients did not meet age eligibility criteria, two were under 18 years 
old and one did not report their age. These patients were excluded, leaving a final sample 
for analysis of 153 patients (139 male and 14 female) who completed online 
questionnaires for the EQ-5D-5L, EQ-VAS, and Haemo-QoL-A on Qualtrics online 
platform. A summary of the demographic data is shown in Table 3: 
 
Table 3: Clinical and Demographic Information 
 
Clinical and Demographic information     
    Total (n=153) 
Age     
  Mean (SD) 37.1 (1.2) 
  Median 33 
  Range 18-73 
      
Gender      
  Male (%) 139 (91%) 
  Female (%) 14 (9%) 
      
Hemophilia Severity     
  Severe [FVIII:C < 1% ] 97 (64%) 
  Moderate [FVIII:C 1-5% ] 34 (22%) 
  Mild [FVIII:C  > 5% ] 21 (14%) 
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Internal Consistency Analysis (Aim 1) 
Cronbach’s α was used to assess the internal consistency reliability of the Haemo-
QoL-A, overall and for each subscale: physical functioning, role functioning, worry, 
consequences of bleeding, emotional impact, and treatment concerns.   
Table 4 shows the results associated with determining Cronbach’s α for each of 
the domains of Haemo-QoL-A. 
 
Table 4: Internal Consistency Reliability Assessed by Cronbach’s α (n=153) 
 
Haemo-QoL-A Domain Number of Items Cronbach's α 
Physical Functioning  9 0.88 
Role Functioning 11 0.92 
Worry  5 0.87 
Consequences of Bleeding 7 0.88 
Emotional Impact  6 0.86 
Treatment Concern  3 0.74 
Total Haemo-QoL-A Score 41 0.97 
 
Internal consistency is considered good to excellent if Cronbach’s α is between 
0.75-0.95 (Rentz et al, 2008). Internal consistency in our study was good to excellent in 
all domains of Haemo-QoL-A except from Treatment Concerns domain (Cronbach’s α of 
0.74). This is consistent with the previous study done by Rentz et al (2008) on Haemo 
QoL A. 
The results show high reliability for the total Haemo-QoL-A and in each domain 
(Cronbach’s α >0.7) with a range of 0.74 to 0.9. Although Cronbach’s α is between 0.75-
0.95 indicates good to excellent internal consistency, Rentz et al (2008) also used 
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Cronbach’s α of 0.7 as the threshold for adequate reliability for an instrument to compare 
groups. It is notable that Treatment Concerns, the smallest subscale consisting of only 3 
items, shows sufficient internal consistency (Cronbach’s α of 0.74). Overall, Haemo-
QoL-A shows very good internal consistency reliability in each domain and in total 
Haemo-QoL-A score. 
 
Convergent Validity (Aim 2)   
We conducted a convergent validity analysis to investigate the construct validity 
of the EQ-5D-5L for use in the hemophilia patient population. Since the Haemo-QoL-A 
was specifically designed to describe HRQoL in hemophilia patients, the degree of 
correlation between Haemo-QoL-A and EQ-5D-5L scores was expected to reflect how 
well the EQ-5D-5L evaluates HRQoL in hemophilia patients. 
Table 5 shows the correlation between each domain of the EQ-5D-5L and Haemo-
QoL-A along with the correlation between the total score obtained from Haemo-QoL-A 
and utilities for the EQ-5D-5L calculated from schedules devised by Cross Walk and 
Direct methods of utility calculation. The correlation between the EQ-VAS score and 
Haemo-QoL-A total score is also shown in the table. 
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Table 5: Pearson Correlations between EQ-5D-5L and Haemo-QoL-A – overall, domain 
and utility scores 
 EQ-5D-5L Domains Scores EQ-5D-5L 
Utilities 
 
Haemo Qol A 
Domains Scores 
Mobility 
 (1-5) 
Self-Care  
(1-5) 
Usual 
Activities 
(1-5) 
Pain 
(1-5) 
Anxiety/ 
Depression 
(1-5) 
Overall 
Score 
Cross 
Walk 
(0-1) 
Overall 
Score 
Direct 
(0-1) 
EQ VAS  
(0-100) 
Physical 
Functioning (0-
5) 0.73 0.53 0.74 0.71 0.38 0.73 0.75 
NA 
Role 
Functioning (0-
5) 0.51 0.53 0.62 0.58 0.47 0.67 0.69 
Worry (0-5) 0.52 0.48 0.58 0.50 0.51 0.64 0.67 
Consequences of 
Bleeding (0-5) 0.35 0.41 0.43 0.38 0.38 0.46 0.50 
Emotional 
Impact (0-5) 0.40 0.43 0.59 0.41 0.55 0.60 0.60 
Treatment 
Concern (0-5) 0.32 0.26 0.34 0.33 0.37 0.43 0.43 
Haemo QoL A 
Total (0-30) 0.56 0.52 0.65 0.57 0.53 0.70 0.72 0.56 
 
Note: EQ-5D-5L scores were recoded to align with the Haemo-QoL-A so that a higher 
number represents better quality of life on both instruments. Convergent validity is 
supported when the items that are expected to be related show a stronger correlation. 
 
The strongest correlations between the items were observed between EQ-5D-5L 
Usual Activities, Mobility, and Pain domains with Physical Functioning domain in 
Haemo-QoL-A. It was hypothesized that a strong correlation would exist between these 
domains as physical functioning may impact, or be impacted by, mobility, usual 
activities, and pain. The weakest correlation is seen between Treatment Concerns in the 
Haemo-QoL-A and all five domains of EQ-5D-5L. Our study results indicate that the EQ-
5D-5L ratings do not reflect the treatment concerns of hemophilia patients.     
To establish the construct validity of the EQ-5D-5L in hemophilia patients we 
expected to find strong correlation between this instrument and the Haemo-QoL-A. We 
used correlation coefficients to quantify the relationship between the two instruments. 
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According to Hays and Hayashi (1990), item convergence is supported with an item 
correlation coefficient of 0.4 or above with the scale it is hypothesized to correlate. Rentz 
(2008) also used a correlation coefficient threshold of 0.4 to determine the correlation 
between Haemo-QoL-A and SF-36 as a generic HRQoL measurement tool.  Using this 
criterion, the construct validity of the EQ-5D-5L utility scores for assessing the HRQoL 
of hemophilia patients is supported for every domain including treatment concerns.  
Similar domains in EQ-5D-5L and Haemo-QoL-A were expected to have 
moderate to strong correlations: 
- Physical functioning and mobility are expected to be strongly correlated. 
- Role functioning and Usual Activities are expected to be strongly correlated. 
- Emotional impact or Worry and Anxiety/Depression are also expected to be 
strongly correlated. 
- Consequences of Bleeding and Pain are also expected to be strongly 
correlated. 
Also, it was expected to find a weak correlation between certain domains: 
- Treatment Concerns and Mobility are not expected to be strongly correlated. 
In addition, the total score obtained from Haemo-QoL-A is expected to be strongly 
correlated with utility scores obtained by using EQ-5D-5L. 
Correlations between the domain scores of EQ-5D-5L and Haemo-QoL-A shows 
that in four similar domains there is a strong correlation of 0.7 (P<0.01 in all cases). EQ-
5D-5L domains of mobility, usual activities, and pain have strong correlations with the 
Haemo-QoL-A physical functioning domain.  However, the correlation between role 
functioning, worry, and emotional impact is within the moderate correlation range (R = 
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0.4 – 0.7). Consequences of bleeding domain is weakly related with mobility, pain, and 
anxiety/depression. Lastly, the treatment concern domain is weakly correlated with all 
EQ-5D-5L domains which suggests that unlike the Haemo-QoL-A, EQ-5D-5L may not 
reflect the impact of treatment concerns on the HRQoL of hemophilia patients.  
Correlations between Haemo-QoL-A total scores and EQ-5D-5L utility scores 
utility scores calculated with Cross Walk and Direct methods are strong and statistically 
significant (P<0.01 for both Cross Walk and Direct methods). EQ VAS scores are 
moderately correlated (R = 0.56, P<0.01) with Haemo-QoL-A total scores. 
 
Floor and Ceiling Effects (Aim 2) 
Table 6 shows the percentage of the responses at the lowest score and the 
percentage of the responses at the highest score to assess floor and ceiling effects in this 
study.  
 
Table 6: Haemo-QoL-A Mean HRQoL Score Distributional Characteristics, Floor and 
Ceiling Effects (n=153) 
Haemo-QoL-A Domains  
Transformed Scores (0-100) 
Mean SD Median Floor (%) Ceiling (%) 
Physical Functioning  63.86 20.95 64.44 8.42% 23.97% 
Role Functioning 72.62 19.78 76.36 5.29% 36.66% 
Worry  69.36 26.92 76.00 9.93% 39.61% 
Consequences of Bleeding 72.18 19.78 74.29 3.64% 34.17% 
Emotional Impact  70.96 21.65 76.67 4.03% 32.79% 
Treatment Concern  69.28 22.46 73.33 6.32% 32.46% 
Total Haemo-QoL-A  69.71 18.58 75.02 6.14% 32.82% 
 
Note: The higher scores mean better HRQoL or less impairment. The Ceiling% represent 
the percentage of the cases with the best HRQoL or the lowest impairment. The Floor% 
represent the worst HRQoL or the highest impairment. 
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The ceiling effect occurs when a high the proportion of subjects that choose the 
maximum score. The floor effect occurs when a high proportion of the study subjects 
choose the minimum possible score. In our analysis of Haemo-QoL-A, the lowest 
possible item score –which represents the worse HRQoL - was seen in 3.6 - 9.9% of 
subjects and the highest item score – which represents the better HRQoL - was seen in 
23.9–31.6% of subjects. No items demonstrated high floor or ceiling effects (i.e. 60% of 
subjects with the lowest and highest score respectively). In other words, more patients 
report a better HRQoL. 
Table 7 also shows floor and ceiling effects in the original 1-5 rating EQ-5D-5L 
responses. 
  
Table 7: EQ-5D-5L Mean HRQoL Score Distributional Characteristics, Floor and Ceiling 
Effects (n=153)   
EQ-5D-5L Domain  
Ratings (1-5) 
Mean SD Median Ceiling (%) Floor (%) 
Mobility 2.19 1.02 2 1.96% 29.41% 
Self-Care 1.29 0.58 1 0.00% 77.12% 
Usual Activities 1.88 0.88 2 0.00% 41.18% 
Pain 2.61 0.93 3 4.58% 8.50% 
Anxiety/Depression 1.99 1.08 2 3.27% 40.52% 
Total EQ-5D-5L 1.99 1.01 2 1.96% 39.35% 
 
Note: The higher scores mean worse HRQoL or more impairment. The Ceiling% 
represent the percentage of the cases with the worst HRQoL or the highest impairment. 
The Floor% represent the best HRQoL or the lowest impairment. 
 
The percentage of the lowest and the highest value responses for each of the 5 
EQ-5D-5L questions – which represents each domain of the instrument -  were calculated 
to determine the floor and ceiling effects. The highest score in EQ-5D-5L represents the 
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lowest quality of life and the lowest score represents the best quality of life. In the ceiling 
analysis, 0% to 4.58% of the participants reported the maximum domain scores, the worst 
HRQoL in EQ-5D-5L. In the floor effect analysis, 8.5% to 77.12% of the participants 
reported the minimum possible score that represents the best HRQoL. In other words, 
more patients reported the better HRQoL.This inconsistent with the floor and ceiling 
effect observed in Haemo-QoL-A. 
Ceiling effect was observed in one item (Self Care) where more than 60% of all 
the subjects were with the highest score. 
 
In Table 8 floor and ceiling effects of the severe hemophilia cases in the research 
are shown. When we just look at the severe hemophilia cases, the high ceiling effect 
disappears for the EQ-5D-5L. 
 
Table 8: EQ-5D-5L Mean HRQoL Score Distributional Characteristics for Severe 
Hemophilia Patients, Floor Effect and Ceiling Effect (n=97) 
 
EQ-5D-5L Domains  
Transformed Scores (0-100) 
Floor (%) Ceiling (%) 
Mobility 1.96% 13.73% 
Self-Care 0.00% 47.71% 
Usual Activities 0.00% 23.53% 
Pain 3.92% 5.23% 
Anxiety/Depression 2.61% 30.07% 
Total EQ-5D-5L 1.70% 24.05% 
 
We looked at floor and ceiling effect to make sure that the instrument covers the 
full range of severity and allowed for discrimination among the patients. In the literature 
there are different floor and ceiling effect thresholds considered to be acceptable for 
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different patient-reported outcomes measurement tools. Rentz et al (2008) determined 
60% as the threshold for high floor and ceiling effect to assess Haemo-QoL-A.  
In the analysis of EQ-5D-5L in severe hemophilia cases, the lowest possible item 
score was seen in 0.0 – 3.9% of subjects and the highest possible item score was seen in 
5.2–47.7% of subjects. Study of floor and ceiling effect in severe hemophilia cases, the 
proportion of the maximum scores (ceiling effect) was lower in comparison with the total 
number of mild, moderate, and severe cases.  
 
Known Group Validation (Aim 2) 
In order to evaluate the construct validity of the EQ-5D-5L relative to the Haemo-
QoL-A in hemophilia patients we compared HRQoL scores across hemophilia severity 
subgroups. We looked at the average scores in each domain of EQ-5D-5L, the average 
utility scores calculated with direct conversion method and crosswalk conversion method, 
and Haemo-QoL-A average total scores separately to find out if the average scores are 
significantly different for mild, moderate, and severe hemophilia cases. We also looked at 
the average scores in each domain of EQ-5D-5L and Haemo-QoL-A in mild, moderate, 
and severe hemophilia patients groups to study the discrimination pattern in each domain 
for each disease severity. 
We transformed EQ-5D-5L responses on to a 1 to 100 scale in order to align the 
scores with Haemo-QoL-A results and have higher scores indicate better quality of life. 
Mean Haemo-QoL-A total scores, utility scores of EQ-5D-5L calculated with 
cross walk method and direct methods, and EQ-VAS scores for each hemophilia severity 
group are shown in figures below.  ANOVA was used to compare reported levels HRQoL 
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across disease severity groups and evaluate how well each measurement tool the 
discriminated between severity groups. 
Figure 1 shows the EQ-5D-5L utility scores obtained with the direct method and 
crosswalk method and converted to 1-100 scale along with the total Haemo-QoL-A score 
and EQ-VAS score in severe, moderate, and mild hemophilia subjects. 
 
Figure 1: Comparison of the mean total scores for Haemo-QoL-A, EQ-5D-5L crosswalk 
values, EQ-5D-5L Direct values, and EQ-5D-VAS in patients with Mild, Moderate, and 
Severe Hemophilia  
 
 
In Table 9 the researcher analyzed total scores of the EQ-5D-5D and Haemo-
QoL-A using ANOVA to determine the association of each domain with the severity of 
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Table 9: ANOVA analysis of Haemo-QoL-A total score and EQ-5D-5L utility scores 
calculated by Cross Walk and Direct methods (n=153) 
 F P-Value F-Critical 
EQ-5D-5L Cross Walk 2.11 0.12 3.06 
EQ-5D-5L Direct Canada 2.63 0.08 3.06 
EQ-VAS 1.78 0.17 3.06 
Haemo-QoL-A 1.33 0.27 3.06 
 
ANOVA showed that the direct conversion EQ-5D-5L utilities  have the highest 
F-statistic to discriminate among the disease severities, but none of the instruments 
significantly distinguished amongst the 3 severity groups. 
Figure 2 shows the scores associated with each domain of EQ-5D-5L converted to 
1-100 scale and separated by the disease severity of the subjects. 
 
Figure 2: Mean EQ-5D-5L adjusted scores in each domain for patients with Mild, 
Moderate, and Severe Hemophilia  
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The mean adjusted domain scores (1-100) based on 1-5 problem rating in each domain of 
EQ-5D-5L and Haemo QoL A evaluated to determine if the instruments can discriminate 
the subjects with mild, moderate, and severe hemophilia.  
Table 10 shows that average EQ-5D-5L adjusted domain scores differed among 
disease severity groups and it is statistically significant in Mobility and Usual Care 
domains.  Mobility and Usual Activities are the domains that are strongly associated with 
the disease severity (F>3.06, P<0.01).  
Table 10: ANOVA Results of EQ-5D-5L domains adjusted scores 1-100 (n=153) 
EQ-5D-5L ANOVA Analysis F P-Value F-Crit 
Mobility 5.14 0.01 3.06 
Self-Care 2.53 0.08 3.06 
Usual Activities 3.86 0.02 3.06 
Pain 1.78 0.17 3.06 
Anxiety/Depression 0.41 0.67 3.06 
 
Figure 3 shows the scores associated with each domain of Haemo-QoL-A separated by 
the disease severity of the subjects. 
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Figure 3: Mean Haemo-QoL-A domain scores for patients with Mild, Moderate, and 
Severe Hemophilia. 
 
 
As shown in Table 11, Haemo-QoL-A domain scores differed significantly across 
disease severity groups for Physical Functioning and Worry (P=0.04 and 0.03, 
respectively).  The differences across groups in Role Functioning scores approached 
significance (P=0.05).   
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The scores associated with each domain of Haemo-QoL-A show a difference 
between the known groups of mild, moderate and severe hemophilia patients. In physical 
functioning, role functioning, and worry domains we observed statistically significant 
differences among the severity types. However, the differences were not statistically 
significant in three other domains – consequences of bleeding, emotional impact, and 
treatment concerns based on the ANOVA results. 
 
Content Validity (Aim 2) 
In order to study the content validity of EQ-5D-5L for hemophilia patients we 
looked at the relationship between responses to individual Haemo-QoL-A questions and 
particular EQ-5D-5L domain responses. We selected Haemo-QoL-A questions 
hypothesized to be related to a particular domain of EQ-5D-5L and correlated the 
responses. EQ-5D-5L responses were transformed so that higher values reflect a better 
quality of life in both instruments: 
 
Table 12: Correlation between EQ-5D-5L domain questions and the related questions in 
Haemo-QoL-A 
EQ-5D-5L 
Domain 
Number of Related Questions 
in Haemo-QoL-A 
Correlation with Related 
Questions in Haemo-QoL-A P-Value 
Mobility 3 0.79 <0.01 
Self-Care 0 N/A N/A 
Usual 
Activities 6 
0.69 <0.01 
Pain/Disco
mfort 2 
0.64 <0.01 
Anxiety/Dep
ression 6 
0.61 <0.01 
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We chose Haemo-QoL-A questions that we thought may be related to the same 
domain question in EQ-5D-5L and looked at the correlation between the mean score of 
the selected Haemo-QoL-A questions with the average score of the related question in 
EQ-5D-5L. A strong correlation between the selected questions suggests that EQ-5D-5L 
domains adequately measure the quality of life in hemophilia patients and may 
demonstrate the content validity of EQ-5D-5L for hemophilia patients. Results show that 
the conceptually similar questions between the Haemo-QoL-A and EQ-5D-5L are 
strongly related. There was no question in haemo-QoL-A that directly relates to self-care 
domain in EQ-5D-5L that asks the subjects about the problem with washing or dressing. 
The strongest correlation was observed in mobility domain (R=0.79, P<0.01) followed by 
usual activities domain (R=0.69, P<0.01). All other domains show moderate to strong 
correlation with correlations ranging from 0.61 – 0.79. 
Moderate to strong correlations between the selected questions related to EQ-5D-
5L domains is suggestive of the relevant subscale for hemophilia patients is adequately 
being measured in each domain of EQ-5D-5L. 
Comparison of EQ-5D-5L Cross Walk and Direct Reference Approaches (Aim 3) 
We looked at the impact of the source of utilities for EQ-5D-5L disease stages on 
the relationship between EQ-5D-5L and Haemo-QoL-A.  Table 13 shows the correlations 
between the EQ-5D-5L utilities scored from a crosswalk mapping function based on the 
older 3-level EQ-5D, utilities based on TTO direct valuations of the EQ-5D-5L conducted 
in Canada, the Haemo-QoL-A and EQ-VAS. 
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Table 13: Correlations between the Haemo QoL A, EQ-5D-5L Crosswalk Utilities, EQ-5D-5L 
Direct Utilities, and EQ-VAS in a Hemophilia Patient Sample (N=153). 
 
Total Score Correlation Haemo-QoL-A 
EQ-5D-5L  
Cross Walk EQ-5D-5L Direct 
Haemo-QoL-A       
EQ5D5L CrossWalk 0.70      
EQ5D5L Direct 0.72  0.95    
EQ VAS 0.56  0.55  0.58  
 
As expected, the Direct and Cross Walk utilities were very highly correlated with 
each other, with a correlation of 0.95 which is close to perfect.  Direct utility scores had 
slightly stronger correlations with the Haemo-QoL-A total score and EQ-VAS than the 
Cross Walk utilities did. These findings suggests that the direct method values for may be 
preferable to the Cross Walk values for converting EQ-5D-5L scores to utility scores for 
hemophilia patients.  
EQ-VAS is moderately correlated with the utility scores in cross walk (R= 0.55) 
and direct (R=0.58) methods. EQ-VAS is also moderately correlated with Haemo-QoL-A 
total score (R=0.56).   Average utility values were very similar between the direct and 
crosswalk methods in all disease severity subgroups. 
Table 14: The comparison of the utility index scores in crosswalk and direct valuation methods. 
 
Characteristic Direct 
Valuation 
Method Utility 
Score 
Standard 
Deviation 
Crosswalk 
Method Utility 
Score 
Standard 
Deviation 
Difference (90% CI) 
All Patients 0.722 0.190 0.720 0.168 0.0018 (0.0254 to 0.0225) 
Mild 0.726 0.192 0.725 0.170 0.0006 (0.0266 to 0.0235) 
Moderate 0.722 0.190 0.720 0.168 0.0018 (0.0254 to 0.0225) 
Severe 0.722 0.191 0.720 0.169 0.0016 (0.0256 to 0.0226) 
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We also used a scattered plot to look at the shape of the relationship between the 
utility scores calculated by Cross Walk and Direct methods. 
 
Figure 4: Scattered Plot of the Utility Scores Obtained from Direct Reference Method 
and the Cross Walk Method of Converting ED-5D-5L Scores to Utility Scores 
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Study of the shape of the distribution of utility scores calculated with cross walk 
and direct methods demonstrates the agreement between the utility scores calculated 
using crosswalk method and the utility scores calculated with the direct method (Figure 
4).  
 
Quality Question Analysis 
We asked the participants about the most significant thing that impacts their 
quality of life. The answers are presented in the table below. Some of the participants 
mentioned more than one factor as the most significant thing that impacts their quality of 
life:   
 
Table 15: Most significant concerns of hemophilia patients   
 
Most Significant Concern Answer Count % 
Pain/Joint damage 81 50% 
Hemophilia Treatment/resources Concerns 18 11% 
Social Life/family/school/work 16 10% 
Money/Financial concerns/Insurance 11 7% 
Physical activity/Ability to run/Walk 11 7% 
Feeling alone/Anxiety/depression 7 4% 
Age 6 4% 
Good education and fewer problems 5 3% 
Internal Bleeding/Bleeding 2 1% 
Adherence to treatment 1 1% 
Weight 1 1% 
Inhibitors 1 1% 
Lack of sleep 1 1% 
Becoming blind due to Hemophilia 1 1% 
 
The number of answers is greater than the total number of 153 participants because some 
of the participants mentioned more than one factor as the most significant thing that 
impacts their quality of life.   
 44 
 
Results show that joint damage and pain is the most significant concern in this 
patient population and accounts for 50% of the answers. This is suggestive of the 
correlation between the Haemo-QoL-A total score and EQ-5D-5L pain domain (r=0.57, 
P<0.01). No other concern is as clearly reflected in the correlations between the specific 
domains of Haemo-QoL-A and EQ-5D-5L but hemophilia treatment and the social life, as 
the main concern of 11% and 10% of the participants respectively, may be consistent with 
the correlation between anxiety/depression domain in EQ-5D-5L and Haemo-QoL-A total 
score.  
The results show that Haemo-QoL-A domain consequences of bleeding and 
treatment factors – that may be related to treatment and resources concerns in the 
qualitative survey- are moderately correlated with utility scores calculated with cross 
walk and direct methods (r = 0.43 - 0.50). But the correlation between emotional impact 
and worry domain scores in Heamo-QoL-A and the utility scores of EQ-5D-5L (for both 
cross walk and direct methods) is stronger and ranges from 0.60 to 0.69. This finding 
suggests that utility scores associated with EQ-5D-5L may be impacted by the emotional 
concerns and worry of the hemophilia patients. 
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Chapter 4 – Discussion  
Reliability of EQ-5D-5L (Aim 1) 
Internal consistency is among the various types of reliability for HRQOL 
measures. Internal consistency refers to the homogeneity of items, that is, the extent to 
which the items of a domain or scale measure the same concept or construct. Cronbach α 
is the most widely used statistical test to assess internal consistency (Lin et al, 2013). The 
minimum level of reliability depends on the type of analysis. In general, reliabilities in 
the 0.50–0.70 range are acceptable for making comparisons between groups (Lin et al, 
2013). Internal consistency has been used to evaluate the reliability of other hemophilia 
specific HRQoL measures. Varaklioti et al (2014) used Cronbach α to study the reliability 
of Haem-A-QoL which is another hemophilia specific HRQoL measurement tool and 
used the 0.70 standard for the group level comparison. Their results show Cronbach α 
value of 0.872 for the total HRQoL score. 
Ferreira et al (2013) also used Cronbach α to evaluate the reliability of Heam-A-
QoL in hemophilia patients with the total Cronbach α value of 0.90 for the total HRQoL 
score. The results of our study in evaluating the internal consistency of Haemo-QoL-A 
show Cronbach α of 0.97 for the total HRQoL score which is suggestive of ab acceptable 
internal consistency of the instrument in hemophilia patient population. 
 
Construct Validity of EQ-5D-5L in Hemophilia Patient Population (Aim 2) 
Our study confirms the construct validity of EQ-5D-5L in hemophilia population, 
and is consistent with previous and recent studies in evaluating HRQoL with PROs in 
hemophilia patient population. Szentes et al (2018) found a good correlation between 
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EQ-5D-5L and the disease-specific King’s Brief Interstitial Lung Disease questionnaire 
(K-BILD) in a German population with evaluating the correlation between the two 
instruments. 
Pederson et al (2018) studied the validity and reliability of the Norwegian version 
of Stroke-Specific Quality of Life (SS-QOL) scale and looked at the correlation between 
this disease-specific QoL measure and EQ-5D-3L as the generic utility based QoL 
measurement tool. Our study is also designed to study the validation and reliability of 
EQ-5D-5L in hemophilia patient population by looking at the correlation between 
hemophilia disease-specific QoL measure and the generic measure.  
However, depending on the different domains associated with each generic PRO 
tool the correlation strength may vary among the different domains. Some studies that 
were performed to compare the disease-specific HRQoL measurement tools with generic 
HRQoL tools did not focus on each domain in the instrument and instead, just studied the 
total scores. Dickerson et al (2018) studied the longitudinal construct validity of generic 
quality of life measures including EQ-5D-3L and looked at the correlation between them 
and the disease specific Quality of Life in Depression Scale (QLDS) in order to 
assessment of change in depression outcomes in teens. They did not look at the scores 
associated with each domain of the measurement tools they studied.  
In general, the similar domains in generic PROs that exhibit the concepts such as 
pain and mobility are more strongly correlated with the similar domains in disease-
specific tools. As a result, the relevant functioning and health domains is an important 
consideration in choosing the appropriate generic instrument for hemophilia population.  
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The maximum score values represent the best HRQoL in Haemo-QoL-A and 
ceiling effect is observed for this measurement tool. In contrast, in EQ-5D-5L a floor 
effect was observed because of the high proportion of the participants who chose the 
lowest possible score. However, Study of floor and ceiling effect in Haemo-QoL-A and 
EQ-5D-5L shows the same trend in which a high proportion of the participants reported 
the best HRQoL score in both instruments. 
 
Mapping (Crosswalk) Utility Conversion Method vs. Direct Utility Conversion 
Method (Aim 3) 
We compared EQ-5D-5L utility values derived from direct valuation or mapping 
approaches. Luo et al (2015) also compared the utility-based EQ-5D-5L index scores 
derived from the mapping and direct valuation approaches for the EQ-5D-5L instrument 
in 269 breast cancer patient population. He regards mapping as a ‘second-best’ approach 
to deriving utility values, although it is accepted by NICE as a legitimate approach to 
generating utility values for CUA. Similar to our study, Luo studied the correlation 
between the utility scores and the disease-specific scores associated with Functional 
Assessment of Cancer Therapy - Breast (FACT-B) questionnaire as a disease-specific 
tool. According Luo’s finding, the valuation-derived index scores were generally higher 
than the mapping-derived index score in patients with similar characteristics. However, 
the magnitude of the difference was small and the corresponding 90 % CI fell within the 
pre-specified equivalence margin for most of the patient groups. The same pattern was 
observed in our study. We also observed slightly higher utility scores obtained with direct 
valuation method in hemophilia patient population with all disease severities. 
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Our study is among the very few studies that directly compare EQ-5D-5L utility 
scores obtained from mapping and direct valuation approaches and it shows similar 
results with same study done on a different patient population. Our study confirms the 
strong correlation between the utility scores obtained from both approaches and the total 
HRQoL scores obtained from the disease-specific tools. We suggest that this pattern may 
be consistent along the other patients’ populations and other diseases. It means that we 
expect to see the same correlation between the utility scores obtained from both 
approaches and the disease-specific HRQoL scores. Besides we expect to see slightly 
higher utility values when we use the direct valuation method for calculating the utility 
scores with a slightly stronger correlation between the disease-specific HRQoL score and 
the utility scores calculated with direct valuation approach. 
We recommend using the utility scores calculated using the direct method of 
utility conversion when possible. The direct method provides stronger correlation with 
hemophilia specific HRQoL scores. However, it is not always possible to use the direct 
method. There are some countries that do not have a health utility value set that is made 
by a direct methodology. In these cases, a value set that is made by mapping method (i.e. 
crosswalk value set) can be used to conduct health utility studies. 
Moreover, the reason for use should also be considered in this respect. EQ-5D-5L 
is a preferred instrument for pharmaceutical economics studies including cost-utility, 
ICER, and resource allocation and decision-making and is a good choice for our research. 
We evaluated the correlation between the utility scores calculated with two different 
methods and the HRQoL scores associated with a disease-specific tool. A demonstrated 
 49 
 
correlation between EQ-5D-5L and Heamo-QoL-A can ensure us about the 
appropriateness of EQ-5D-5L for economic studies in hemophilia patient populations.  
 
Hemophilia Disease-Specific Tools vs. Generic Tools 
Over the last decades, the focus of hemophilia care and the outcome of factor 
replacement therapy has become very important in different contexts, including adjusting 
treatment for individual patients, justification of costs and the evaluation of efficacy and 
costs of new concentrates. Hemophilia treatment is becoming more effective and more 
expensive in the same time. Disease-specific measures are helpful for the healthcare 
providers in evaluating the clinical decisions in hemophilia population. Grongeri and Von 
Mackensen (2008) listed 6 hemophilia disease-specific tools for measuring HRQoL in 
children and 5 disease-specific tools to be used for adults. Haemo-QoL-A is a relatively 
new disease-specific tool that is developed by Anne Rentz. It is relatively short and easy 
to be answered by the patients and covers all of the relevant areas associated with 
hemophilia disease.  
HRQoL and patient reported outcomes is another context that may provide 
information for the decision makers in respect with evaluating the different clinical 
procedures as well as the resource allocation decisions. Although, the patient reported 
outcomes should be used appropriately to lead to the right conclusions.  
The concerns about the content coverage of EQ-5D-5L for a given disease-
specific application have been raised before. Lin et al (2013) did a research on the public 
literature at the time and looked at the content of disease-specific instruments in cancer, 
coronary artery disease, osteoarthritis, rheumatoid arthritis, obesity, and stroke and 
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concluded that the unique content of some of the disease-specific tools are not covered in 
EQ5D. They recommended that EQ5D descriptive system should be enhanced. We 
studied the application of EQ-5D-5L in hemophilia patients that is a patient population 
that was not studied by Lin. We also used the newer EQ-5D-5L along with the utility 
index scores obtained from direct and mapping methods and looked at the overall 
correlation between the two instruments. 
We studied a hemophilia-specific specific HRQoL measurement tool, Haemo-
QoL-A, and its correlation with a much shorter and easier to fill, generic HRQoL 
measurement tool, EQ-5D-5L, and looked at the correlation between this two instruments 
to determine if EQ-5D-5L is reliable, valid, and relevant enough to be used in hemophilia 
patient population. A summary of all materials and statistical methods that were used for 
analyzing our results and drawing our conclusions is available on Appendix 4. 
Disease-specific HRQoL tools are more comprehensive than the generic ones in 
covering all of the relevant factors that may impact the quality of life of the patients for 
that specific disease. They can also be used to calculate the utility scores for that 
particular disease. But they can only be used for one disease. And the methods of 
calculating the utilities is different for each disease-specific tool. That’s why the utility 
scores are not equivalent and comparable with the utility scores obtained from another 
disease-specific tool. Generic HRQoL tools have the advantage of being able to be 
applied to all of the diseases with any disease severity or patient status. This is considered 
an advantage when the resource allocation decisions include different diseases. When the 
outcomes of the health interventions are determined by the utilities, a uniform method to 
calculate the utilities in different methods will be helpful. We wanted our study to be 
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simple, easy to use, and be applicable to the patient with different health status, 
languages, and culture and EQ-5D-5L as a short and easy to fill HRQoL questionnaire 
could serve this purpose.    
 
Response Burden  
An important feature of our research was the feasibility and ease of 
administration. EQ-5D-5L is a short questionnaire that can easily be distributed among 
the patients in paper hard copies, through emails, or through the platforms such as 
Qualtrics. A previous meta-analysis study done by Rolstad et al (2009) shows that the 
response rates are lower for longer questionnaires. The higher than anticipated response 
rate to our questionnaires in our study as well as the low missing data rate suggests that a 
short and simple questionnaire along with an easy and convenient mode of administration 
result in a high response rate and low missing data. Besides, in our study we tried to 
demonstrate that a short generic HRQoL measurement tool such as EQ-5D-5L that is 
appropriate for economic evaluations is a valid tool to be used in hemophilia population. 
Kaye et al (2012) studied the importance of the patients’ involvement in biomedical 
research as well as the increasing awareness of the value of patient involvement in 
research. Our study is one of the few studies that leverages the value of the direct 
hemophilia patient involvement in conducting the research. Besides, we created a concise 
questionnaire that is preferred by the participants based on the previous studies (Van 
Geest et al, 2007). 
We asked our patients to openly discuss about the important problems in respect 
with their disease and our research method. Skinner et al (2018) point to the continuously 
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increasing interest of health care agencies, private payers, and policy makers for PROs. 
According to them, there is a substantial need to improve capacity to collect and interpret 
relevant PRO data to support implementation of patient-centered research and advocacy 
to obtain optimal care in hemophilia.  
Application of EQ5D and its role in healthcare reimbursement is also being 
studied in many health systems around the world. Davlin (2013) studied the National 
Institute of Care Excellence (NICE) case and brought up the question of whether the new 
health technologies are good value for the money. Since we need cost effectiveness 
analysis for providing a means of comparing the value of money, we require standardized 
measures of health outcomes such as QALY.  
We tried to include the aforementioned advantages in our research design. The 
electronic versions of the questionnaires or the link to open them can be easily sent to the 
smartphones or computers of the participants. Moreover, the participants should only 
answer the 5 questions instead of filling a long disease-specific questionnaire. The results 
of our study demonstrates the validity of EQ-5D-5L for hemophilia population.  
In addition, the ease of use and the feasibility of the study design to be used in 
hemophilia population may provide an advantage for the health policy makers to gather 
fast and reliable patient reported outcomes data to be used for resource allocating 
purposes in developing countries. EQ-5D-5L is available in more than 130 languages and 
in various modes of administration. There are many publication from the developing 
countries in which EQ-5D-5L is used for evaluating the HRQoL in hemophilia patients. 
Cost-utility studies that can be done by using the utility scores calculated from EQ-5D-5L 
can help the decision makers to allocate the budget for importing the medications. Our 
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study demonstrates the possibility of using a fast and easy to administer tool that is short, 
valid, and reliable tool such as EQ-5D-5L can also help the decision makers to evaluate 
the health outcomes associated with hemophilia medications and take patients’ preference 
into account.  
 
One Disease at a Time  
As it was discussed earlier in this research, EQ-5D-5L is a HRQoL measurement 
tool that can be used for all of the diseases. It is a patient-reported outcomes tool that can 
be used by the patients and providers independent from the disease. One of the big 
questions about this tool is whether it is applicable to all diseases. When we compare EQ-
5D-5L results to Haemo-QoL-A we found that there are specific domains of the disease-
specific tool that are not strongly correlated with any of the individual domains of EQ-
5D-5L. We speculate that this trend may be consistent with what is observed in other EQ-
5D-5L versus the disease-specific tools in other diseases. The reason is that EQ-5D-5L is 
a short questionnaire that cannot include all the details that may be specific to a particular 
disease.  
However, our results show that when the domain scores are combined together 
and are converted to the utility scores – either with the mapping method or with the direct 
method of conversion – the overall utility scores are strongly correlated with the overall 
scores obtained from the disease-specific tool. The same trend has been observed in many 
different diseases and in other researches that compared EQ-5D utility scores to the 
overall HRQoL scores obtained from the disease -specific tools as we cited earlier in this 
document. (Szentes et al, 2018 – Pederson et al, 2018). 
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However, the selection of the generic or disease-specific tools for measuring the 
quality of life or the utilities depends on the study objectives, the study design, and the 
target population as well. For instance, if the study is designed to compare two or more 
different diseases or to compare the HRQoL of a patient population to that of the general 
population it is best to use the generic tools. According to O'Connor (2004) a 
comprehensive assessment of HRQoL would ideally combine three questionnaires: a 
disease-specific questionnaire to target the condition, a treatment-specific questionnaire 
to target the intervention, and a generic questionnaire to allow comparison with 
population norms and/or other health conditions. 
Our study results along with the other findings from the other studies suggest that 
the correlation between the utility scores in EQ-5D-5L is consistent among the other 
diseases as well. We believe the comparison between the individual disease-specific tools 
with EQ-5D-5L may provide confirmatory evidence about the strong correlation between 
the utility scores and the overall HRQoL scores and provide more evidence for the 
validity and reliability of EQ-5D-5L in hemophilia patient population. We think it is the 
best to choose a questionnaire that has a proven track record in research that had been 
studied in similar objectives and target populations whenever possible.  
 
Study Limitations 
The questionnaire link was emailed to the registered hemophilia patients by Rare 
Patient Voice. The researcher could not verify that the form was filled by the patients or 
the caregivers. The women participants in this study is 9%. Hemophilia is an X-link 
recessive disease and most of the hemophilia cases are male patients. However, it is 
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possible that some of the participants have a female gender identity or have participated 
in the study as caregivers. 
Coding of the qualitative data was done by the researcher. Reviewing the coding 
data by multiple judges could enhance the rigor of the study. 
 
Conclusion 
The results of our study demonstrate a relatively strong correlation between the 
utility scores obtained from EQ-5D-5L and the total scores of Haemo-QoL-A. Moderate 
to strong correlations also exist between the conceptually related individual domains of 
each instrument between the domains that measure a similar concept (i.e. mobility and 
physical functioning). 
Overall, the validity of EQ-5D-5L instrument for using in hemophilia population 
is supported by our study of the correlations between the utility scores obtained from 
direct and mapping methods with the HRQoL scores obtained from Haemo-QoL-A. The 
results demonstrate that direct method of converting EQ-5D-5L scores to utility score 
provided higher correlation with the total Haemo-QoL-A score. The utility scores 
calculated by cross walk method also show slightly weaker correlation with the disease-
specific Haem-A-QoL tool. We conclude  that the direct utility index development 
technique to may be the best option for converting the scores to utilities and is strongly 
correlated with Haemo-QoL-A scores as a gold standard for evaluating HRQoL in 
hemophilia patients. 
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Recommendations 
We recommend the use of EQ-5D-5L utility scores calculated with direct method 
for cost utility studies in hemophilia patient population. The statistical analysis of our 
results support the content and construct validity of the EQ-5D-5L for hemophilia 
patients.  When hemophilia patients’ domain scores were converted to utilities using a 
schedule from a direct valuation of EQ-5D-5L disease states, correlations between the 
EQ-5D-5L and hemophilia-specific measures were slightly stronger than when a cross 
walk derived schedule was used for conversion. Therefore, we recommend other 
researchers use a direct valuation utility schedule whenever possible with EQ-5D-5L for 
CUAs with hemophilia patients. 
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Appendix 1: Rare Patient Voice Email Template 
Hi {First Name}, 
Thanks for being a member of Rare Patient Voice. We have an opportunity for you 
to take part in a xxx study for Patients. Our project number for this study is ABC_1234. 
Project Details: 
Web-Based Online Questionnaires about Hemophilia Quality of Life (you must be 
by a computer or a smart phone with high-speed internet access during the time of the 
interview) 
The questionnaire will approximately take 30 minutes to get completed. 
$10 Gift Card Reward will be provided to the participants 
Things to Note: 
Adult Patient (18+) study only, Caregivers please pass the link along 
Unique links, please do not pass along for 2nd use 
Want to share this opportunity? Let us know and we can provide a new link 
Please use a laptop/computer ONLY. No smartphones or tablets - Preliminary 
questions are Mobile Friendly!  
Save this email to reference if you have any questions about the study!  
If you are interested in this study, please click the link below to answer a few 
questions to see if you qualify.  
Study Link: https://umn.qualtrics.com/jfe/form/SV_eDuGkWubj60AEiV 
Thanks as always for your participation! Please be aware that by entering this 
information you are not guaranteed that you will be selected to participate. As always, we 
do not share any of your contact information without your permission. 
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Not interested in this study? (Click link below so we do not send you any 
reminders for this study) 
Study Opt Out Link: {Unique Opt Out Link} 
We truly appreciate the time you set aside to interact with our company and don’t 
take it for granted. Receive a $10 gift card for referring others who may want to 
participate in this or future studies. Invite them to join Rare Patient Voice: 
www.rarepatientvoice.com/sign-up. They, too, receive a gift card. 
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Appendix 2: Scoring Manual for Haemo-QoL-A 
Items are answered on a 6-point Likert-type scale, ranging from 0 (None of the 
time) to 5 (All of the time).  Higher scores mean better HRQL or less impairment for a 
particular subscale. 
Recoding items 
Some items are positively worded and some are negatively worded.  Negatively 
worded items should be reverse scored so that higher scores reflect better quality of life.  
The item scores of negatively worded items should be subtracted from 5.  For example: 
Question 1 is a negatively worded item so it should be scored: 
 
(5 – Question 1) = Score of reverse scored Question 1. 
 
The positively worded items are the following: 3, 6, 7, 9, 12, 16, 19, 32, and 
34.  All other items are negative and should be reverse scored. 
Scoring 
For the Haemo-QoL-A subscales [physical functioning, role functioning, worry, 
consequences of bleeding, emotional impact (formerly: positive affect), treatment 
concern], scores are computed by averaging across the items within a subscale.  The 
range of subscale scores is 0 to 5; higher scores mean better HRQL or less impairment for 
a particular subscale. 
To calculate the Haemo-QoL-A total score, sum the value of the individual subscales (do 
not sum all the individual items).  The range of total scores is 0 to 30; higher scores mean 
better HRQL or less impairment. 
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For both total and subscale scores, use the formula below to transform raw scores to a 0 
to 100 scale.  Higher scores will be indicative of better HRQL. 
Missing Items 
For the subscale analyses, if < 50% of the scale items are missing, the scale 
should be retained with the mean scale score of the items present used to impute a score 
for the missing items.  If > 50% of the items are missing, no scale score should be 
calculated, the subscale score should be considered missing.  If a subscale score is 
missing, the Haemo-QoL-A total score cannot be calculated   
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Items by subscale: 
SAS Variable Name Number Scoring 
Physical Functioning 
rHQ3 1 Reverse 
rHQ4 2 Reverse 
HQ5 3  
rHQ7 5 Reverse 
HQ8 6  
HQ9 7  
rHQ10 8 Reverse 
HQ12 9  
rHQ14 10 Reverse 
Role Functioning 
rHQ6 4 Reverse 
rHQ21 17 Reverse 
rHQ25 21 Reverse 
rHQ26 22 Reverse 
rHQ31 26 Reverse 
rHQ33 28 Reverse 
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rHQ37 31 Reverse 
rHQ39 33 Reverse 
rHQ45 36 Reverse 
rHQ46 37 Reverse 
rHQ48 38 Reverse 
Worry 
rHQ28 23 Reverse 
rHQ29 24 Reverse 
rHQ30 25 Reverse 
rHQ32 27 Reverse 
rHQ34 29 Reverse 
Consequences of Bleeding 
rHQ15 11 Reverse 
rHQ17 13 Reverse 
rHQ18 14 Reverse 
rHQ19 15 Reverse 
rHQ22 18 Reverse 
rHQ24 20 Reverse 
rHQ36 30 Reverse 
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Emotional Impact 
HQ16 12  
HQ20 16  
HQ23 19  
HQ38 32  
HQ43 34  
rHQ44 35 Reverse 
Treatment Concern 
rHQ49 39 Reverse 
rHQ51 40 Reverse 
rHQ52 41 Reverse 
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Scale  
 
Average the Item 
Values 
Lowest
/Highest 
Possible Raw 
Scores 
Range 
Physical 
functioning 
(1+2+3+5+6+7+8+
9+10) 
9 
0, 5 5 
Role 
functioning 
(4+17+21+22+26+
28+31+ 33+36+37+38) 
11 
0, 5 5 
Worry  
(23+24+25+27+29) 
5 
0, 5 5 
Consequences 
of bleeding 
(11+13+14+15+18
+20+30) 
7 
0, 5 5 
Emotional 
impact 
(12+16+19+32+34
+35) 
6 
0, 5 5 
Treatment 
concern 
(39+40+41) 
3 
0, 5 5 
Haemo-QoL-A 
Total  
Sum of subscales 
(not individual 
items) 
0, 30 30 
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Formula for transformation of the Haemo-QoL-A total raw score: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transformed Score = 
Actual raw total score 
Possible raw score range 
x 100 
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Appendix 3: Haemo-QoL-A Questions Related to each EQ-5D-5L Domain 
 
EQ-5D-5L 
Domain 
Questions Expected to have the 
same answer 
Question 
Number 
Mobility Loss of joint mobility affects how I 
walk 
H1 
It is hard for me to climb the stair H2 
I am unable to leave the house 
because of my hemophilia. 
H4 
Usual 
Activities 
It is easy for me to perform daily 
activities. 
H3 
It is easy for me to lift heavy 
objects. 
H7 
I am able to participate in sports. H9 
I experience restrictions at work or 
school. 
H25 
My hemophilia treatment interferes 
with my daily activities. 
H37 
I feel I can carry out a normal life 
like the rest of society. 
H34 
Pain/Disco
mfort 
I have to adjust my activities 
because of pain. 
H5 
I feel frustrated because I can't do 
what I want to do. 
H21 
Anxiety/De
pression 
My infusions for hemophilia are 
stressful. 
H38 
I feel like a burden to my family. H26 
I am hopeful about the future. H12 
I feel less confident than others. H15 
I enjoy life. H16 
I feel much older than my years. H17 
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Appendix 4: Summary of Aims and Methodologies 
Aim No. Topic Study Aim Methods Used 
I Reliability 
Internal Consistency of Haemo-
QoL-A Domains Cronbach's α 
II Construct Validity 
EQ-5D-5L Overall Scores and 
Scores in each Domain 
Mean Scores, SD, Floor and 
Ceiling Effect 
Haemo-QoL-A Overall Scores 
and Scores in each Domain 
Mean Scores, SD, Floor and 
Ceiling Effect 
Correlation Between EQ-5D-5L 
and Haemo-QoL-A Correlation Coefficient 
Sensitivity to Disease Severity - 
Overall and Domain Scores ANOVA, Mean Scores, SD 
III Content Validity 
Correlation between EQ-5D-5L 
and Haemo-QoL-A Related 
Questions Correlation Coefficient 
IV 
Conversion 
Method  
Comparison 
Correlation of EQ-5D-5L Overall 
Scores obtained from 
Crosswalk and Direct Methods 
with Haemo-QoL A and EQ-VAS 
Scores Correlation Coefficient 
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